Health Economics›Esophageal cancer›Neoadjuvant chemoradiotherapy

Neoadjuvant chemoradiotherapy

Esophageal cancer · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Capecitabine, Docetaxel, Oxaliplatin, RT Variant #01	—	R 6 389	35d	—	—	—	—	—
Capecitabine, Carboplatin, Paclitaxel, RT Variant #01	—	R 4 874	42d	—	—	—	—	—
Capecitabine, Docetaxel, RT Variant #01	—	R 3 883	35d	—	—	—	—	—
Capecitabine, Oxaliplatin, RT Variant #01	—	R 3 843	35d	—	—	—	—	—
Carboplatin and Paclitaxel (CP) and RT Variant #01	—	R 3 785	35d	—	—	—	—	1
Capecitabine and Cisplatin (CX) and RT Variant #03	—	R 3 674	42d	—	~34.5 mo	—	—	1
Carboplatin, Fluorouracil, RT Variant #01	—	R 3 616	35d	—	—	—	—	—
Fluorouracil, Oxaliplatin, RT Variant #01	—	R 3 608	42d	—	—	—	—	—
Capecitabine, Paclitaxel, RT Variant #01	—	R 2 661	35d	—	—	—	—	—
Cisplatin, Irinotecan, RT Variant #01	—	R 2 267	35d	—	—	—	—	—
Cisplatin and Fluorouracil (CF) and RT Variant #13	—	R 1 850	28d	16.0 mo	53.8 mo	18	R 33 301 PFS proxy	2
Docetaxel, Fluorouracil, RT Variant #01	—	R 1 000	45d	—	—	—	—	—
Cisplatin and Paclitaxel (TP) and RT N/A - secondary systemic drug	—	R 350	28d	—	—	—	—	1
Cisplatin and Docetaxel (DC) and RT N/A - secondary systemic drug	—	R 176	—	—	—	—	—	—

14 of 14 regimens shown